Clinical Trials List
Protocol NumberCABL001A2001B
Active
2022-10-27 - 2030-08-30
Phase III
Recruiting1
ICD-10C92.10
Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
ICD-10C92.12
Chronic myeloid leukemia, BCR/ABL-positive, in relapse
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9205.10
Chronic myeloid leukemia, without mention of remission
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- HSUAN JEN SHIH 無
- 高小雯 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
1 participants
-
Global
390 participants
